ArticleFrontiers in immunology2026
Monocyte TLR2/4 as predictive biomarkers for progression from dengue warning signs to severe disease.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The World Health Organization (WHO) classification system, comprising dengue fever (DF), dengue with warning signs (DWS), and severe dengue (SD), has been widely adopted globally; however, clinical management remains challenging. Current warning sign criteria lack specificity, frequently failing to distinguish patients progressing to severe disease from those with transient illness, thereby contributing to delayed interventions and missed therapeutic windows. Although Toll-like receptors (TLRs) mediate innate antiviral immunity and are implicated in severe dengue pathogenesis, their expression dynamics during the critical DWS transition window, a phase in which intervention could prevent progression to severe disease, remain entirely unknown. Methods: An integrated biomarker discovery study was conducted, comprising bioinformatics analysis of publicly available single-cell RNA sequencing (scRNA-seq) data (GSE220969) and experimental validation in an independent clinical cohort of 45 dengue patients and 10 healthy controls (H) in Guangdong Province, China. Phase-specific immune signatures were identified from the scRNA-seq data. TLRs expression was quantified by multiparameter flow cytometry. Diagnostic performance was assessed using ROC curve analysis, and correlations with clinical laboratory parameters were evaluated using Spearman's rank correlation. Results: Bioinformatics analysis of 23 cell clusters revealed that TLR2/4/7/8 expression peaked specifically during the DWS phase, predominantly in monocytes. Flow cytometry confirmed elevated surface TLR2 (AUC 0.874) and TLR4 (AUC 0.763) in DWS versus other phases, with discriminatory capacity to distinguish DWS from SD (TLR2: AUC 0.833; TLR4: AUC 0.810). Moreover, correlation analysis of TLRs expression with clinical indicators demonstrated that the expression levels of TLR2 and TLR4 were associated with the development of SD. Conclusions: Elevated monocyte TLR2/4 expression during DWS identifies patients at risk for progression to severe dengue before clinical decompensation. These mechanism-informed biomarkers provide a foundation for point-of-care risk stratification in endemic regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.